Why the study?
Does long-term anticoagulation provide a favorable balance of risks and benefits in elderly patients with chronic atrial fibrillation?
Does long-term anticoagulation provide a favorable balance of risks and benefits in elderly patients with chronic atrial fibrillation?
This review highlights the lack of definitive evidence for long-term anticoagulation in elderly patients with chronic atrial fibrillation, calling for a large randomized trial.
Answers are grounded in this paper and cite their sources.
Anticoagulation decisions in elderly AF warrant caution amid uncertain risk-benefit; leaves open the need for a definitive RCT.
Chronic atrial fibrillation is generally thought to cause stroke by atrial thrombus formation with subsequent embolization. Rheumatic heart disease previously led to most cases of atrial fibrillation, but recent substantial declines in the incidence of rheumatic fever have changed the distribution of causes of atrial fibrillation. Elderly patients have an appreciable prevalence of chronic atrial fibrillation. The risks and potential benefits of long-term anti-coagulation for elderly patients with atrial fibrillation are discussed and the quality of the evidence assessed. It is concluded that the evidence is sufficiently incomplete and imperfect for a large, well-designed trial to be needed; however, this would be difficult and expensive.
No takes yet. Share an insight, caveat, or question.
DV Wilson (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: